Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS)

American Journal of Hematology

Volumn 81, Issue 2, 2006, Pages 81-85

  Rao, V Koneti ^a,b,c,d   Carrasquillo, Jorge A ^a,b,c,d   Dale, Janet K ^a,b,c,d   Bacharach, Stephen L ^a,b,c,d   Whatley, Millie ^a,b,c,d   Dugan, Faith ^a,b,c,d   Tretler, Jean ^a,b,c,d   Fleisher, Thomas ^a,b,c,d   Puck, Jennifer M ^a,b,c,d   Wilson, Wyndham ^a,b,c,d   Jaffe, Elaine S ^a,b,c,d   Avila, Nilo ^a,b,c,d   Chen, Clara C ^a,b,c,d   Straus, Stephen E ^a,b,c,d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

18F fluro 2 deoxy D glucose; Coombs Direct Anti Globulin Test; DAT; DNT; Double negative T cells; FDG; PET; Postiron emission tomography; Regions of interest; ROIS; Standardized uptake value; SUV

Indexed keywords

CARDIOLIPIN ANTIBODY; CORTICOSTEROID; FAS ANTIGEN; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; THYROID ANTIBODY;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; BURKITT LYMPHOMA; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 8; COOMBS TEST; DEVICE; DIAGNOSTIC VALUE; FEMALE; GENE MUTATION; GLOMERULONEPHRITIS; HEPATOSPLENOMEGALY; HUMAN; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; SPLENECTOMY;

AUTOIMMUNE DISEASES; BIOPSY; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC DISEASES; LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; MALE; MUTATION; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES;

EID: 32144452579     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20523     Document Type: Article

References (26)

1. Sneller MC, Wang J, Dale JK, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997;89: 1341-1348.
2. Jackson CE, Fischer RE, Hsu AP, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet 1999;64(4):1002-1014.
3. Lim MS, Straus SE, Dale JK, et al. Pathological findings in human autoimmune lymphoproliferative syndrome. Am J Pathol 1998;153:1541-1550.
4. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-946.
5. Vaishnaw AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, Elkon KB. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest 1999;103: 355-363.
6. Puck JM, Straus SE. Somatic mutations-not just for cancer anymore. N Engl J Med 2004;351:1388-1390.
7. Holzelova E, Vonarbourg C, Stolzenberg MC, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med 2004;351:1409-1419.
8. Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome (ALPS) with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001;98:194-200.
9. Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004;31: 22-28.
10. Lucignani G, Paganelli G, Bomabardieri E. The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun 2004;25:651-656.
11. Burton C, Ell P, Linch D. The role of PET imaging in lymphoma. Br J Haematol 2004;126:772-784.
12. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995;36:1790-1796.
13. Dobert N, Menzel C, Berner U, et al. Positron emission tomography in patients with Hodgkin's disease: correlation to histopathologic subtypes. Cancer Biother Radiopharm 2003;18:565-571.
14. Bental M, Deutsch C. Metabolic changes in activated T cells-an NMR study of human peripheral blood lymphocytes. Magn Reson Med 1993;29:317-326.
15. Brand KA, Hermfisse U. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J 1997;11:388-395.
16. Takalkar A, Yu JQ, Kumar R, Xiu Y, Alavi A, Zhuang H. Diffuse bone marrow accumulation of FDG in a patient with chronic myeloid leukemia mimics hematopoietic cytokine-mediated FDG uptake on positron emission tomography. Clin Nucl Med 2004;29:637-639.
17. Zhuang HM, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002;32:47-59.
18. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18- fluorodeoxyglucose uptake. J Nucl Med 1994;35:104-112.
19. Kung J, Zhuang H, Yu JQ, Duarte PS, Alavi A. Intense fluorodeoxyglucose activity in pulmonary amyloid lesions on positron emission tomography. Clin Nucl Med 2003;28:975-976.
20. Yu JQ, Zhuang H, Xiu Y, Talati E, Alavi A. Demonstration of increased FDG activity in Rosai-Dorfman disease on positron emission tomography. Clin Nucl Med 2004;29:209-210.
21. Tartar M, Kipper MS. Positron emission tomography findings of autoimmune lymphoproliferative syndrome. Mol Imaging Biol 2004;6:124-125.
22. Hain SF, O'Doherty MJ, Bingham J, Chinyama C, Smith MA. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours? Nucl Med Commun 2003;24:1139-1143.
23. Toretsky J, Levenson A, Weinberg IN, Tait JF, Uren A, Mease RC. Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death. Nucl Med Biol 2004;31:747-752.
24. Mankoff DA, Dehdashti F, Shields AF. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia 2000;2:71-88.
25. van den Bossche B, van de Wiele C. Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol 2004;22:3593-3607.
26. Jackson CE, Fischer RE, Hsu AP, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet 1999;64:1002-1014.